Consistent with our findings, the protein arginine methyltransferase (PRMT) type 1 inhibitor MS023 has been shown to re-induce differentiation in CRC and to increase expression of differentiation markers such as CDX2 [68]. Here, CDX2 is linked to colorectal carcinoma.